

ENZON PHARMACEUTICALS INC
Form 8-K
March 24, 2011

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549**

FORM 8-K

**CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported) March 21, 2011

ENZON PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)

Delaware 0-12957 22-2372868
(State or other jurisdiction of incorporation) (Commission File No.) (IRS Identification No.)

20 Kingsbridge Road, Piscataway, New Jersey 08854
(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code (908) 541-8600

685 Route 202/206, Bridgewater, New Jersey, 08807
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- o Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - o Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - o Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On March 21, 2011, Ivan D. Horak, M.D., the President of Research and Development and Chief Scientific Officer of Enzon Pharmaceuticals, Inc. ("Enzon"), tendered his resignation, which shall be effective April 4, 2011. Pursuant to Dr. Horak's employment agreement with Enzon, filed as Exhibit 10.1 to Enzon's Quarterly Report on Form 10-Q for the quarter ended September 30, 2005 filed on November 9, 2005, Dr. Horak is not entitled to receive any severance payment in connection with his resignation.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: March 24, 2011

By: /s/ Andrew Rackear
Andrew Rackear
Vice President and General
Counsel
